Clinical Study On The Therapy With Autologous Dendritic Cells Co-cultured With CIK Cells In Advanced Malignancies

Objective:To investigate curative efficacy of DC-CIK cell-therapy on patients with metastatic renal carcinoma, NSCLC and advanced gastric cancer.Methods:Automatically collect peripheral blood mononuclear cells (PBMCs) with a COBE Spectra blood cell separator from twenty-two patients with metastatic renal carcinoma,12males and10females,age from49to79years old,IV stage of22cases. The cytotoxic activity and proliferation of DC-CIK cells were assessed. Each patient accepted autologous DC-CIK intravenous infusion with one month interval. The safety and immunological index such as lymphocyte subsets and cytokine concentration were detected both before and one week after DC-CIK infusion. Forty-three patients with advanced NSCLC,26males and17females, age from46to80years old,ⅢB stage of18cases, IV stage of25cases,who were treated with DC-CIK therapy. T lymphocyte subtypes and intra-cellular cytokines in peripheral blood of the patients were analyzed, Performance Status (KPS) and clinical effects were observed. The safety were also observed. Twenty-eight patients with advanced gastric cancer,21males and7females,age from41to77years old,IV stage of28cases,who were treated with DC-CIK combined with chemotherapy were taken as the combined treatment group, the other twenty-eight patients with advanced gastric cancer,22males and6females, age from39to79years old,IV stage of28cases,who were treated with chemotherapy alone during the same period were taken as control. T lymphocyte subtypes, intra-cellular cytokines in peripheral blood of the patients and Performance Status (KPS) were compared between the two groups. The clinical effects were analysed. The safety were observed.Results:DC-CIKs displayed significant killing activities to renal cancer cell line786-0and K562in vitro. There is no significant change in T lymphocyte subtypes after DC-CIK treatment.Two patients experienced a transient fever, and one felt a short time of fatigue after DC-CIKs infusion. Compared to the cytokine levels prior to DC-CIK infusion, the sera levels of interleukine2(IL-2), interleukin12(IL-12) and interferon gamma(IFN-r) improved significantly with the increase rates54.55%(12/22),81.82%(18/22) and86.36%(19/22) as well as P value<0.005.The ratios of CD3+,CD4+,CD56+andCD4+/CD8+increased after treatment, which showed significant statistical difference (P<0.05).The therapy increased IL-2,IL-12,IFN-γ and TNF-α level after treatment,(P<0.05).The disease control rate (DCR) was53.49%.The effective rate of KPS was83.72%.on patients with advanced NSCLC.The ratios of CD3+,CD4+,CD56+andCD4+/CD8+were not changed obviously in combined treatment group and decreased in control group after treatment on patients with advanced gastric cancer, which showed significant statistical difference (P<0.05). The IL-12and IFN-Y were increased after treatment in combined treatment group,(P<0.05). The IL-2, IL-12and TNF-a were decreased in control group after treatment (P<0.05). The disease control rate (DCR) of combined therapy group and control group were78.6%and53.6%respectively showing significant difference (P<0.05). The effective rate of KPS were82.14%and57.14%respectively showing significant difference (P<0.05).Conclusions:DC-CIK cell-therapy can improve immune functions and elevate life quality of the patients with metastatic renal carcinoma、NSCLC and advanced gastric cancer. DC-CIK cell-therapy is likely to be an effective adoptive immunotherapy for malignancies...